Inflammation based regulation of cancer cachexia

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Onesti, Jill K ^a,b   Guttridge, Denis C ^b,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CELECOXIB; CYTOKINE; ETANERCEPT; GEMCITABINE; INTERLEUKIN 6; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX7; TUMOR NECROSIS FACTOR ALPHA;

CACHEXIA; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR MECHANICS; MUSCLE ATROPHY; NONHUMAN; PANCREAS CANCER; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE; SOLID TUMOR; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY; WASTING SYNDROME;

ANIMALS; CACHEXIA; CYTOKINES; HUMANS; INFLAMMATION; MUSCLE, SKELETAL; NEOPLASMS; WASTING SYNDROME;

EID: 84901757447     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/168407     Document Type: Review

References (87)

1. Wallengren O., Lundholm K., Bosaeus I., Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity, and survival in unselected palliative care patients. Support Care Cancer 2013 21 6 1569 1577 10.1007/s00520-012-1697-z
2. Fearon K., Strasser F., Anker S. D., Bosaeus I., Bruera E., Fainsinger R. L., Jatoi A., Loprinzi C., MacDonald N., Mantovani G., Davis M., Muscaritoli M., Ottery F., Radbruch L., Ravasco P., Walsh D., Wilcock A., Kaasa S., Baracos V. E., Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology 2011 12 5 489 495 2-s2.0-79955399340 10.1016/S1470-2045(10)70218-7
3. Thoresen L., Frykholm G., Lydersen S., Ulveland H., Baracos V., Prado C. M. M., Birdsell L., Falkmer U., Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clinical Nutrition 2013 32 1 65 72 10.1016/j.clnu.2012.05.009
4. von Haehling S., Anker S. D., Cachexia as a major underestimated and unmet medical need: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle 2010 1 1 1 5 10.1007/s13539-010-0002-6
5. Prado C. M., Sawyer M. B., Ghosh S., Lieffers J. R., Esfandiari N., Antoun S., Baracos V. E., Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? The American Journal of Clinical Nutrition 2013 98 4 1012 1019 10.3945/ajcn.113.060228
6. Martin L., Birdsell L., Macdonald N., Reiman T., Clandinin M. T., McCargar L. J., Murphy R., Ghosh S., Sawyer M. B., Baracos V. E., Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology 2013 31 12 1539 1547 10.1200/JCO.2012.45.2722
7. Trajkovic-Vidakovic M., de Graeff A., Voest E. E., Teunissen S. C. C. M., Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Critical Reviews in Oncology/Hematology 2012 84 1 130 148 2-s2.0-84858992722 10.1016/j.critrevonc. 2012.02.011
8. Tan B. H. L., Birdsell L. A., Martin L., Baracos V. E., Fearon K. C. H., Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clinical Cancer Research 2009 15 22 6973 6979 2-s2.0-72549086598 10.1158/1078-0432.CCR-09-1525
9. Englesbe M. J., Lee J. S., He K., Fan L., Schaubel D. E., Sheetz K. H., Harbaugh C. M., Holcombe S. A., Campbell D. A., Sonnenday C. J., Wang S. C., Analytic morphomics, core muscle size, and surgical outcomes. Annals of Surgery 2012 256 2 255 261 10.1097/SLA.0b013e31826028b1
10. Englesbe M. F., Terjimanian M. N., Lee J. S., Sheetz K. H., Harbaugh C. M., Hussain A., Holcombe S. A., Sullivan J., Campbell D. A., Wang S. C., Sonnenday C. J., Morphometric age and surgical risk. Journal of the American College of Surgeons 2013 216 5 976 985 10.1016/j.jamcollsurg.2013.01.052
11. Miller B. S., Ignatoski K. M., Daignault S., Lindland C., Doherty M., Gauger P. G., Hammer G. D., Wang S. C., Doherty G. M., Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World Journal of Surgery 2012 36 7 1509 1516 2-s2.0-84859888447 10.1007/s00268-012-1581-5
12. Sabel M. S., Lee J., Cai S., Englesbe M. J., Holcombe S., Wang S., Sarcopenia as a prognostic factor among patients with stage III melanoma. Annals of Surgical Oncology 2011 18 13 3579 3585 2-s2.0-82955248074 10.1245/s10434-011-1976-9
13. Bachmann J., Ketterer K., Marsch C., Fechtner K., Krakowski-Roosen H., Büchler M. W., Friess H., Martignoni M. E., Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009 9, article 255 2-s2.0-70349847241 10.1186/1471-2407-9- 255
14. Peng P., Hyder O., Firoozmand A., Kneuertz P., Schulick R. D., Huang D., Makary M., Hirose K., Edil B., Choti M. A., Herman J., Cameron J. L., Wolfgang C. L., Pawlik T. M., Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. Journal of Gastrointestinal Surgery 2012 16 8 1478 1486 10.1007/s11605-012-1923-5
15. Harimoto N., Shirabe K., Yamashita Y. I., Ikemagi T., Yoshizumi T., Soejima Y., Ikeda T., Maehara Y., Nishie A., Yamansaka T., Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. British Journal of Surgery 2013 100 11 1523 1530 10.1002/bjs.9258
16. Sabel M. S., Terjimanian M., Conlon A. S. C., Griffith K. A., Morris A. M., Mulholland M. W., Englesbe M. J., Holcombe S., Wang S. C., Analytic morphometric assessment of patients undergoing colectomy for colon cancer. Journal of Surgical Oncology 2013 108 3 169 175 10.1002/jso.23366
17. Ravasco P., Monteiro-Grillo I., Marques Vidal P., Camilo M. E., Cancer: disease and nutrition are key determinants of patients' quality of life. Supportive Care in Cancer 2004 12 4 246 252 2-s2.0-2442642565 10.1007/s00520-003-0568-z (Pubitemid 38660747)
18. Vaughan V. C., Martin P., Lewandowski P. A., Cancer cacheia: impact, mechanisms and emerging treatments. Journal of Cachexia, Sarcopenia and Muscle 2013 4 2 95 109 10.1007/s13539-012-0087-1
19. Prado C. M. M., Baracos V. E., McCargar L. J., Mourtzakis M., Mulder K. E., Reiman T., Butts C. A., Scarfe A. G., Sawyer M. B., Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clinical Cancer Research 2007 13 11 3264 3268 2-s2.0-34250656139 10.1158/1078-0432.CCR- 06-3067 (Pubitemid 46944911)
20. Prado C. M. M., Baracos V. E., McCargar L. J., Reiman T., Mourtzakis M., Tonkin K., Mackey J. R., Koski S., Pituskin E., Sawyer M. B., Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical Cancer Research 2009 15 8 2920 2926 2-s2.0-65249138226 10.1158/1078-0432.CCR-08-2242
21. Andreyev H. J. N., Norman A. R., Oates J., Cunningham D., Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer 1998 34 4 503 509 2-s2.0-0032033321 10.1016/S0959-8049(97)10090-9 (Pubitemid 28179346)
22. Dalal S., Hui D., Bidaut L., Lem K., del Fabbro E., Crane C., Reyes-Gibby C. C., Bedi D., Bruera E., Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. Journal of Pain and Symptom Management 2012 44 2 181 191 10.1016/j.jpainsymman.2011.09.010
23. Solheim T. S., Blum D., Fayers P. M., Hjermstad M. J., Stene B. G., Strasser F., Kaasa S., Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod?-analysis from a multicenter cross sectional study. Acta Oncologica 2014 53 4 539 546 10.3109/0284186X.2013. 823239
24. Richards C. H., Roxburgh C. S. D., MacMilla M. R., Isswiasi S., Robertson E. G., Guthrie G. K., Horgan P. G., McMillan D. C., The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS ONE 2012 7 8 e41883 10.1371/journal.pone. 0041883
25. Trutschnigg B., Kilgour R. D., Morais J. A., Lucar E., Hornby L., Molla H., Vigano A., Metabolic, nutritional and inflammatory characteristics in elderly women with advanced cancer. Journal of Geriatric Oncology 2013 4 2 183 189 10.1016/j.jgo.2012.09.002
26. Wu J., Huang C., Xiao H., Tang Q., Cai W., Weight loss and resting energy expenditure in male patients with newly diagnosed esophageal cancer. Nutrition 2013 29 11 1310 1314 10.1016/j.nut.2013.04.010
27. Xiao G. Q., Liu C., Liu D. L., Yang J. Y., Yan L. N., Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. World Journal of Gastroenterology 2013 19 45 8398 8407 10.3748/wjg.v19.i45.8398
28. Jin Y., Ye X., He C., Zhang B., Zhang Y., Pretreatment neutrophil-to-lymphocyte ratio as predictor survival for patients with metastatic nasopharyngeal carcinoma. Head & Neck 2014 10.1002/hed.23565
29. Jankova L., Dent O. F., Chan C., Chapuis P., Clarke S. J., Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of noe-positive colorectal cancer. BMC Cancer 2013 13, article 442 10.1186/1471-2407-13-442
30. Nakamura T., Matsumine A., MAtsubara T., Asanuma K., Uchida A., Sudo A., The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma. Journal of Surgical Oncology 2013 108 7 481 485 10.1002/jso.23424
31. Jin H., Zhang G., Liu X., Chen C., Yu H., Huang X., Zhang Q., Yu J., Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World Journal of Surgical Oncology 2013 11, article 112 10.1186/1477-7819-11-112
32. Dutta S., Crumley A. B. C., Fullarton G. M., Horgan P. G., McMillan D. C., Comparison of the prognostic value of tumour-and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World Journal of Surgery 2011 35 8 1861 1866 2-s2.0-80051554435 10.1007/s00268-011- 1130-7
33. McMillan D. C., An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proceedings of the Nutrition Society 2008 67 3 257 262 2-s2.0-49549097136 10.1017/S0029665108007131
34. Iwaku A., Kinoshita A., Onoda H., Fushiya N., Matsushima M., Tajiri H., The Glasgow prognostic score accurately predicts survivial in patients with biliary tract cancer not indicated for surgical resection. Medical Oncology 2014 31 1, article 787 10.1007/s12032-013-0787-1
35. Kishiki T., Masaki T., Matsuoka H., Kobayashi T., Suzuki Y., Abe N., Mori T., Sugiyama M., Modified Glasgow prognositc score in patients with incurable stage IV colorectal cancer. The American Journal of Surgery 2013 206 2 234 240 10.1016/j.amjsurg.2012.07.051
36. Shafique K., Proctor M. J., McMillan D. C., Leung H., Smith K., Sloan B., Morrison D. S., The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer 2013 13 1, article 292 10.1186/1471-2407-13-292
37. McMillan D. C., The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treatment Reviews 2013 39 5 534 540 10.1016/j.ctrv.2012.08.003
38. Stene G. B., Helbostad J. L., Blastad T. R., Riphagen I. I., Kaasa S., Oldrevoll L. M., Effect of physical exercise on muscle mass and strength in cancer patients during treatment-a systematic review. Critical Reviews in Oncology/Hematology 2013 88 3 573 593 10.1016/j.critrevonc.2013.07.001
39. Tisdale M. J., Biology of cachexia. Journal of the National Cancer Institute 1997 89 23 1763 1773 2-s2.0-0030665384 (Pubitemid 27516230)
40. Costa G., Cachexia, the metabolic component of neoplastic diseases. Cancer Research 1977 37 7 2327 2335 2-s2.0-0017760424 (Pubitemid 8220282)
41. Evans W. K., Makuch R., Clamon G. H., Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Research 1985 45 7 3347 3353 2-s2.0-0021833470 (Pubitemid 15007216)
42. Drott C., Svaninger G., Lundholm K., Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. Annals of Surgery 1988 208 5 645 650 2-s2.0-0023787065 (Pubitemid 18267709)
43. Holm E., Hagmuller E., Staedt U., Schlickeiser G., Gunther H.-J., Leweling H., Tokus M., Kollmar H. B., Substrate balances across colonic carcinomas in humans. Cancer Research 1995 55 6 1373 1378 2-s2.0-0028920328
44. Mulligan H. D., Tisdale M. J., Metabolic substrate utilization by tumour and host tissues in cancer cachexia. Biochemical Journal 1991 277 2 321 326 2-s2.0-0025816139
45. Emery P. W., Edwards R. H. T., Rennie M. J., Protein synthesis in muscle measured in vivo in cachectic patients with cancer. British Medical Journal 1984 289 6445 584 586 2-s2.0-0021129631 (Pubitemid 14009869)
46. Llovera M., Garcia-Martinez C., Agell N., Marzabal M., Lopez-Soriano F. J., Argiles J. M., Ubiquitin gen expression is increased in skeletal muscle of tumour-bearing rats. FEBS Letters 1994 338 3 311 318 10.1016/0014-5793(94)80290- 4 (Pubitemid 24056743)
47. Khal J., Wyke S. M., Russell S. T., Hine A. V., Tisdale M. J., Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. British Journal of Cancer 2005 93 7 774 780 2-s2.0-27144505161 10.1038/sj.bjc.6602780 (Pubitemid 41486437)
48. Strassmann G., Fong M., Kenney J. S., Jacob C. O., Evidence for the involvement of interleukin 6 in experimental cancer cachexia. The Journal of Clinical Investigation 1992 89 5 1681 1684 2-s2.0-0026689535
49. Tsujinaka T., Fujita J., Ebisui C., Yano M., Kominami E., Suzuki K., Tanaka K., Katsume A., Ohsugi Y., Shiozaki H., Monden M., Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. The Journal of Clinical Investigation 1996 97 1 244 249 2-s2.0-13344261948 (Pubitemid 26022595)
50. Strassmann G., Fong M., Freter C. E., Windsor S., D'Alessandro F., Nordan R. P., Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. The Journal of Clinical Investigation 1993 92 5 2152 2159 2-s2.0-0027488473 (Pubitemid 23333518)
51. Tamura S., Ouchi K. F., Mori K., Endo M., Matsumoto T., Eda H., Tanaka itsuka H., Tokita H., Yamaguchi K., Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clinical Cancer Research 1995 1 11 1353 1358 2-s2.0-0028792545
52. Scott H. R., McMillan D. C., Crilly A., McArdle C. S., Milroy R., The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. British Journal of Cancer 1996 73 12 1560 1562 2-s2.0-0030018821 (Pubitemid 26235384)
53. Zhou X., Wang J. L., Lu J., Song Y., Kwak K. S., Jiao Q., Rosenfeld R., Chen Q., Boone T., Simonet W. S., Lacey D. L., Goldberg A. L., Han H. Q., Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010 142 4 531 543 2-s2.0-77955642517 10.1016/j.cell.2010.07.011
54. Argiles J. M., Lopez-Soriano F. J., The role of cytokines in cancer cachexia. Medicinal Research Reviews 1999 19 3 223 248 (Pubitemid 29198276)
55. Gordon J. N., Green S. R., Goggin P. M., Cancer cachexia. Quarterly Journal of Medicine 2005 98 11 779 788 2-s2.0-27744507351 10.1093/qjmed/hci127 (Pubitemid 41631328)
56. Tisdale M. J., Tumor-host interactions. Journal of Cellular Biochemistry 2004 93 5 871 877 2-s2.0-17844367971 10.1002/jcb.20246 (Pubitemid 44264142)
57. de Visser K. E., Coussens L. M., The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunology, Immunotherapy 2005 54 11 1143 1152 2-s2.0-25844490025 10.1007/s00262-005-0702-5 (Pubitemid 41396818)
58. Coussens L. M., Raymond W. W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G. H., Hanahan D., Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development 1999 13 11 1382 1397 2-s2.0-0033151608 (Pubitemid 29270244)
59. Langstein H. N., Norton J. A., Mechanisms of cancer cachexia. Hematology/Oncology Clinics of North America 1991 5 1 103 123 2-s2.0-0026027679
60. Watanabe T., Shibata M., Nishiyama H., Soeda S., Furukawa S., Gonda K., Takenoshita S., Fujimori K., Serum levels of rapid turnover porteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncology Letters 2013 7 2 373 377
61. Yang L., DeBusk L. M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L. M., Carbone D. P., Lin P. C., Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004 6 4 409 421 2-s2.0-5444225991 10.1016/j.ccr.2004.08.031 (Pubitemid 39361441)
62. Coussens L. M., Tinkle C. L., Hanahan D., Werb Z., MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000 103 3 481 490 2-s2.0-0034721666
63. Winfield R. D., Delano M. J., Pande K., Scumpia P. O., LaFace D., Moldawer L. L., Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. Journal of Parenteral and Enteral Nutrition 2008 32 6 651 655 2-s2.0-54249120376 10.1177/0148607108325075
64. Baltgalvis K. A., Berger F. G., Pena M. M. O., Davis J. M., Muga S. J., Carson J. A., Interleukin-6 and cachexia in A P c M i n / + mice. American Journal of Physiology: Regulatory Integrative and Comparative Physiology 2008 294 2 R393 R401 2-s2.0-38949137388 10.1152/ajpregu.00716.2007 (Pubitemid 351213743)
65. White J. P., Puppa M. J., Sato S., Gao S., Price R. L., Baynes J. W., Kostek M. C., Matesic L. E., Carson J. A., IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the A P c M i n / + mouse. Skeletal Muscle 2012 2, article 14 10.1186/2044-5040-2-14
66. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K., Tisdale M., Characterization of a cancer cachectic factor. Nature 1996 379 6567 739 742 2-s2.0-0030063921 10.1038/379739a0 (Pubitemid 26061738)
67. Lorite M. J., Thompson M. G., Drake J. L., Carling G., Tisdale M. J., Mechanism of muscle protein degradation induced by a cancer cachectic factor. British Journal of Cancer 1998 78 7 850 856 2-s2.0-0031656804 (Pubitemid 28430012)
68. Monitto C. L., Dong S.-M., Jen J., Sidransky D., Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clinical Cancer Research 2004 10 17 5862 5869 2-s2.0-4444384629 10.1158/1078-0432.CCR-04-0435 (Pubitemid 39180967)
69. Cabal-Manzano R., Bhargava P., Torres-Duarte A., Marshall J., Bhargava P., Wainer I. W., Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. British Journal of Cancer 2001 84 12 1599 1601 2-s2.0-0035875488 10.1054/bjoc.2001.1830 (Pubitemid 32612489)
70. Tisdale M. J., Are tumoral factors responsible for host tissue wasting in cancer cachexia? Future Oncology 2010 6 4 503 513 2-s2.0-77950605203 10.2217/fon.10.20
71. Whitehouse A. S., Tisdale M. J., Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF- B. British Journal of Cancer 2003 89 6 1116 1122 2-s2.0-0141887308 10.1038/sj.bjc.6601132 (Pubitemid 37239221)
72. Li Y.-P., Reid M. B., NF- B mediates the protein loss induced by TNF- α in differentiated skeletal muscle myotubes. American Journal of Physiology: Regulatory Integrative and Comparative Physiology 2000 279 4 R1165 R1170 2-s2.0-0033696398
73. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y., In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Molecular Biology of the Cell 2004 15 3 1101 1111 2-s2.0-1542283812 10.1091/mbc.E03-09-0704 (Pubitemid 38316219)
74. Penna F., Costamagna D., Pin F., Camperi A., Fanzani A., Chiarpotto E. M., Cavallini G., Bonelli G., Baccino F. M., Costelli P., Autophagic degradation contributes to muscle wasting in cancer cachexia. The American Journal of Pathology 2013 182 4 1367 1378 10.1016/j.ajpath.2012.12.023
75. Reed S. A., Sandesara P. B., Senf S. M., Judge A. R., Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. The FASEB Journal 2012 26 3 987 1000 2-s2.0-84857695549 10.1096/fj.11-189977
76. Acharyya S., Ladner K. J., Nelsen L. L., Damrauer J., Reiser P. J., Swoap S., Guttridge D. C., Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. The Journal of Clinical Investigation 2004 114 3 370 378 2-s2.0-4043154377 10.1172/JCI200420174 (Pubitemid 39071609)
77. Bonetto A., Aydogdu T., Kunzevitzky N., Guttridge D. C., Khuri S., Koniaris L. G., Zimmers T. A., STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011 6 7 2-s2.0-79960611800 10.1371/journal.pone.0022538 e22538
78. Watchorn T. M., Waddell I., Dowidar N., Ross J. A., Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF- B and STAT3. The FASEB Journal 2001 15 3 562 564 2-s2.0-0035293048
79. Penna F., Costamagna D., Fanzani A., Bonelli G., Baccino F. M., Costelli P., Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS ONE 2010 5 10 2-s2.0-78149425900 10.1371/journal.pone. 0013604 e13604
80. He W. A., Berardi E., Cardillo V. M., Acharyya S., Aulino P., Thomas-Ahner J., Wang J., Bloomston M., Muscarella P., Nau P., Shah N., Butchback M. E. R., Ladner K., Adamo S., Rudnicki M. A., Keller C., Coletti D., Montanaro F., Guttridge D. C., NF- B-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. The Journal of Clinical Investigation 2013 123 11 4821 4835 10.1172/JCI68523
81. Relaix F., Wei X.-J., Wu X., Sassoon D. A., Peg3/Pw1 is an imprinted gene involved in the TNF-NF B signal transduction pathway. Nature Genetics 1998 18 3 287 291 2-s2.0-0031906851 10.1038/ng0398-287 (Pubitemid 28117271)
82. Coletti D., Yang E., Marazzi G., Sassoon D., TNF α inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. The EMBO Journal 2002 21 4 631 642 2-s2.0-0037083867 10.1093/emboj/21.4.631 (Pubitemid 34174044)
83. Op den Kamp C. M., Langen R. C., Snepvangers F. J., de Theije C. C., Schellenkens J. M., Laugs F., Dingemans A. M., Schols A. M., Nuclear transcription factor B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. The American Journal of Clinical Nutrition 2013 98 3 738 748 10.3945/ajcn.113.058388
84. Cai D., Frantz J. D., Tawa N. E. Jr., Melendez P. A., Oh B.-C., Lidov H. G. W., Hasselgren P.-O., Frontera W. R., Lee J., Glass D. J., Shoelson S. E., IKK β /NF- B activation causes severe muscle wasting in mice. Cell 2004 119 2 285 298 2-s2.0-5444262078 10.1016/j.cell.2004.09.027 (Pubitemid 39360909)
85. MacCiò A., Madeddu C., Gramignano G., Mulas C., Floris C., Sanna E., Cau M. C., Panzone F., Mantovani G., A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecologic Oncology 2012 124 3 417 425 2-s2.0-84856689893 10.1016/j.ygyno.2011.12.435
86. Wu C., Fernandez S. A., Criswell T., Chidiac T. A., Guttridge D., Villalona-Calero M., Bekaii-Saab T. S., Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 2013 42 5 813 818 10.1097/MPA.0b013e318279b87f
87. Mantovani G., MacCiò A., Madeddu C., Serpe R., Antoni G., Massa E., Dessì M., Panzone F., Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. Journal of Molecular Medicine 2010 88 1 85 92 2-s2.0-75749118481 10.1007/s00109-009-0547-z